Skip to main content

MoneyWorks4Me

Biocon informs about press release

18 Nov 2026 Evaluate
Biocon has informed that it enclosed the press release titled ‘Biocon’s Pertuzumab Gets Marketing Authorization in EU, First Biosimilar Approved Under New Tailored Clinical Approach’. The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
Sun Pharma. Inds. 1872.30
Dr. Reddys Labs. 1396.00
Cipla 1420.00
Lupin 1968.95
Zydus Lifesciences 1195.00
View more..